CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

SINOVAC BIOTECH LTD

SVA
$465MSmall Cap

Next catalyst

Phase 3January 2027

Experimental vaccine

Poliomyelitis

Get an email about SVA's next catalysts

Track SINOVAC BIOTECH (SVA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 3 readout).See the timeline

Catalyst Timeline

3 upcoming, 1 past

Phase 3Next

experimental vaccine Phase 3 Est. Readout

January 2027~Experimental vaccine1,040

Estimated primary completion for experimental vaccine trial (NCT07505836) in Epidemic Meningitis. Topline data typically follows completion by weeks to months.

Source
Phase 3

experimental vaccine Phase 3 Est. Readout

April 2027~Experimental vaccine1,040

Estimated primary completion for experimental vaccine trial (NCT07505810) in Epidemic Meningitis. Topline data typically follows completion by weeks to months.

Source
Phase 3

Inactivated Hepatitis A Vaccine (Human Diploid Cell) Phase 3 Est. Readout

Q3 2027~QInactivated Hepatitis A Vaccine (Human Diploid Cell)680

Estimated primary completion for Inactivated Hepatitis A Vaccine (Human Diploid Cell) trial (NCT07793227) in Hepatitis A Vaccine. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaBEIJING
Drug Pipeline

Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly

Phase 3

Covid19

PROVARIX

Phase 3

Varicella (Chickenpox)

36-71 months old children-experimental EV71 vaccine

Phase 3

Hand, Foot and Mouth Disease

investigational 23-valent PPV

Phase 3

Pneumococcal Infections

Investigational sIPV

Phase 3

Poliomyelitis

EV71 vaccine

Phase 3

Hand, Foot and Mouth Disease

three consecutive lots of EV71 vaccine

Phase 3

Hand, Foot and Mouth Disease

Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

Phase 3

Poliomyelitis

Quadrivalent influenza vaccine

Phase 3

Seasonal Influenza

sIPV-sIPV-bOPV vaccination schedule

Phase 3

Poliomyelitis

Trivalent influenza vaccine (contains B/Victoria strain)

Phase 3

Seasonal Influenza

sIPV-bOPV-bOPV vaccination schedule

Phase 3

Poliomyelitis

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Phase 3

Seasonal Influenza

Experimental vaccine

Phase 3

Poliomyelitis

bivalent enterovirus vaccine (Vero cell), inactivated

Phase 3

Hand, Foot, and Mouth Disease(HFMD)

Sabin Strain Inactivated Poliovirus Vaccine

Phase 3

Poliomyelitis

Participants will receive one dose of vaccine of Sinovac QIV

Phase 3

Influenza

Investigational tetanus vaccine, adsorbed

Phase 3

Tetanus

Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

Phase 3

Covid19

Vaccine manufactured at commercialized scale

Phase 3

Varicella

Sinovac PCV13

Phase 3

Pneumococcal Infectious Disease

investigational live attenuated mumps vaccine

Phase 3

Mumps

control live attenuated mumps vaccine

Phase 3

Mumps

Inactivated COVID-19 Vaccine

Phase 3

COVID-19

Investigational live attenuated varicella vaccine

Phase 3

Varicella

COVID-19 Vaccine,Inactivated

Phase 3

COVID-19

Varicella Vaccine

Phase 3

Varicella

COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)

Phase 3

COVID-19

SARS-CoV-2 Inactivated Vaccine

Phase 3

COVID-19

Sinovac rabies vaccine

Phase 3

Rabies (Healthy Volunteers)

SARS-CoV-2 vaccine (inactivated)

Phase 3

SARS-CoV2 Infection

Inactivated Hepatitis A Vaccine (Human Diploid Cell)

Phase 3

Hepatitis A Vaccine

Trivalent influenza vaccine(BV)

Phase 3

Seasonal Influenza

Adsorbed COVID-19 (inactivated) Vaccine

Phase 3

COVID-19

Trivalent influenza vaccine(BY)

Phase 3

Seasonal Influenza

Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age

Phase 3

Poliomyelitis

Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age

Phase 3

Poliomyelitis

Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

Phase 3

Covid19

Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule

Phase 2

COVID-19

Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule

Phase 2

COVID-19

Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Phase 2

COVID-19

Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule

Phase 2

COVID-19

High-dose experimental vaccine

Phase 2

Herpes Zoster

Sinovac Low-dosage PCV24

Phase 2

Pneumococcal Infectious Disease

CoronaVac®

Phase 2

COVID-19

medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

Phase 2

Hand, Foot and Mouth Disease

Sinovac Middle-dosage PCV24

Phase 2

Pneumococcal Infectious Disease

Omicron Vaccine

Phase 2

COVID-19

Single-dose regimen of high dosage investigational sIPV

Phase 2

Poliomyelitis

Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule

Phase 2

COVID-19

Tetanus Toxoid

Phase 2

Tetanus

pandemic influenza vaccine (H5N1 strain NIBRG-14)

Phase 2

Pandemic Influenza

EV71 vaccine with adjuvant

Phase 2

Infection, Viral, Enterovirus

SNA02-48

Phase 2

Tetanus

split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Phase 2

Influenza

Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)

Phase 2

Hand, Foot, and Mouth Disease (HFMD)

Sinovac High-dosage PCV24

Phase 2

Pneumococcal Infectious Disease

Three-dose regimen of high dosage investigational sIPV

Phase 2

Poliomyelitis

Three-dose regimen of low dosage investigational sIPV

Phase 2

Poliomyelitis

Low-dose experimental vaccine

Phase 2

Herpes Zoster

low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

Phase 2

Hand, Foot and Mouth Disease

Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)

Phase 2

Hand, Foot, and Mouth Disease (HFMD)

high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

Phase 2

Hand, Foot and Mouth Disease

Trivalent Vaccine

Phase 2

COVID-19

COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

Phase 2

COVID-19

Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule

Phase 2

COVID-19

EV71 vaccine without adjuvant

Phase 2

Infection, Viral, Enterovirus

Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Phase 2

COVID-19

Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule

Phase 2

COVID-19

Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule

Phase 2

COVID-19

Oral hexavalent reassortant rotavirus attenuated live vaccine

Phase 2

Rotavirus Gastroenteritis

Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule

Phase 2

COVID-19

Sinovac PCV24

Phase 2

Pneumococcal Infectious Disease

Single-dose regimen of medium dosage investigational sIPV

Phase 2

Poliomyelitis

Three-dose regimen of medium dosage investigational sIPV

Phase 2

Poliomyelitis

High-dose tetravalent inactivated enterovirus vaccine (Vero cell))

Phase 2

Hand, Foot, and Mouth Disease (HFMD)

Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Phase 2

COVID-19

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in SINOVAC BIOTECH LTD's drug pipeline?→

CatalystAlert tracks 77 drug candidates in SINOVAC BIOTECH LTD's (SVA) pipeline across Phase 3, Phase 2. Its lead program is Experimental vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is SINOVAC BIOTECH LTD's next FDA catalyst?→

SINOVAC BIOTECH LTD's (SVA) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track SVA biotech catalysts?→

Add SVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SINOVAC BIOTECH LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply